0001493152-22-007885.txt : 20220328 0001493152-22-007885.hdr.sgml : 20220328 20220328161725 ACCESSION NUMBER: 0001493152-22-007885 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220328 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220328 DATE AS OF CHANGE: 20220328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MARRONE BIO INNOVATIONS INC CENTRAL INDEX KEY: 0001441693 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 205137161 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36030 FILM NUMBER: 22775681 BUSINESS ADDRESS: STREET 1: 7780-420 BRIER CREEK PARKWAY STREET 2: RALEIGH CITY: RALEIGH STATE: NC ZIP: 27617 BUSINESS PHONE: 530-750-2800 MAIL ADDRESS: STREET 1: 7780-420 BRIER CREEK PARKWAY STREET 2: RALEIGH CITY: RALEIGH STATE: NC ZIP: 27617 FORMER COMPANY: FORMER CONFORMED NAME: MARRONE ORGANICS INNOVATIONS INC DATE OF NAME CHANGE: 20080801 8-K 1 form8-k.htm
0001441693 false 0001441693 2022-03-28 2022-03-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 28, 2022

 

 

 

MARRONE BIO INNOVATIONS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-36030   20-5137161
(State or Other Jurisdiction   (Commission   (I.R.S. Employer
of Incorporation)   File Number)   Identification No.)

 

7780-420 Brier Creek Parkway, Raleigh, NC 27617

(Address of Principal Executive Offices, and Zip Code)

 

(530) 750-2800

Registrant’s Telephone Number, Including Area Code

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.00001 par value   MBII   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On March 28, 2022, Marrone Bio Innovations, Inc. (the “Company”) issued a press release announcing and will hold a press conference regarding its results of operations for the fourth quarter and fiscal year ended December 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this report.

 

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02, including Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

   Description
     
99.1   Press release issued on March 28, 2022 by Marrone Bio Innovations, Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MARRONE BIO INNOVATIONS, INC.
     
Date: March 28, 2022 By: /s/ Linda V. Moore
  Name: Linda V. Moore
  Title: Chief Legal Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results

 

RALEIGH, N.C., March 28, 2022 – Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include:

 

● Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.
● Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.
● For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively.
● As announced March 16, 2022, Marrone Bio and Bioceres Crop Solutions (NASDAQ: BIOX) have entered into a definitive agreement to combine the companies in an all-stock transaction.

 

Selected Financial Highlights

 

$ in millions 

Q4

2021

  

Q4

2020

   % Increase (Decrease)  

FY

2021 

  

FY

2020

   % Increase (Decrease) 
Revenues  $10.8   $7.7    40.2%  $44.3   $38.4    15.5%
Gross Profit  $6.5   $4.9    31.5%  $27.2   $22.9    19.1%
Gross Margin   59.7%   63.7%   -400 bps    61.5%   59.6%   +190 bps 
Operating Expenses  $12.1   $9.0    34.2%  $42.7   $40.1    6.5%
Operating Expense Ratio   111.6%   116.6%   -500 bps    96.3%   104.4%   -820 bps 
Net Income (Loss)  $(5.3)  $(4.2)   26.2%  $(16.6)  $(20.2)   (17.9%)
Adjusted EBITDA1  $(4.0)  $(2.2)   78.7%  $(8.7)  $(11.0)   (21.2%)
Cash Used in Operations  $(3.4)  $(7.4)   (53.9%)  $(10.0)  $(16.0)   (37.6%)

 

1Adjusted EBITDA is a non-GAAP financial measure and is described in relation to its most directly comparable GAAP measure under “Use of Non-GAAP Financial Information” below.

 

Management Commentary

 

“We ended 2021 on a positive note, with high demand for our crop protection products ahead of the Northern Hemisphere growing season,” said Chief Executive Officer Kevin Helash. “We delivered solid revenue growth and higher gross profit in both the fourth quarter and full year. These results were in line with our prior projections and set the stage for our future growth.

 

 

 

 

“Looking forward, we anticipate revenue growth for the first half of 2022 will significantly outpace our rate of growth in the first half of 2021, with sales in the second quarter exceeding those in the first quarter, in line with our typical pattern,” Helash added.

 

Helash concluded, “On March 16, 2022, we announced our intention to merge with Bioceres. We look forward to completing the transaction in the third quarter of 2022.”

 

Fourth Quarter 2021 Financial and Operational Summary

 

  ○ Strong demand for the company’s crop protection products for use in specialty crops in the United States — notably Regalia® biofungicide, and Venerate® and Grandevo® bioinsecticides — were the key contributors to the 40.2% increase in 2021 fourth quarter revenues.
  ○ Gross profit in the 2021 fourth quarter was $6.5 million, as compared with $4.9 million in the fourth quarter of 2020, a 31.5% improvement. Gross margins of 59.7% were slightly lower than in the same period in 2020 as a function of product mix.
  ○ Operating expenses were $12.1 million in the fourth quarter of 2021, as compared with $9.0 million in the fourth quarter of 2020. The 34.2% increase reflected higher legal and consulting expenses, primarily related to merger and acquisition activities, and one-time, upfront payments associated with research and development (R&D) agreements.
  ○ The operating expense ratio – a key performance indicator that compares operating expenses to revenues – improved by 500 basis points to 111.6% as sales increased at a higher rate than costs.
  ○ The net loss in the fourth quarter was $5.3 million in 2021, as compared with a net loss of $4.2 million in the fourth quarter of 2020. Fourth-quarter Adjusted EBITDA was a loss of $4.0 million in 2021, as compared with $2.2 million in 2020. Both the net loss and Adjusted EBITDA reflected the higher operating expenses in the quarter. Adjusted EBITDA is further described under “Use of Non-GAAP Financial Information” below.
  ○ Cash used in operations was $3.4 million, as compared with a use of cash of $7.4 million in the same period in 2020.

 

Full Year 2021 Financial and Operational Summary

 

  ○ Full year 2021 revenues of $44.3 million were a 15.5% increase from full year 2020 revenues of $38.4 million. The company recorded continued strong sales of seed treatments for the major row crops in the United States and Europe. Sales of bioprotection products in specialty crops expanded, although the pace of sales was slowed by drought conditions early in the year in the western United States.
  ○ Gross profit rose 19.1% for the full year, with gross margins up 190 basis points to 61.5% as a result of product mix and manufacturing improvements.
  ○ Operating expenses of $42.7 million, a 6.5% increase, were in line with the company’s commitment to maintain spending in line with 2020, plus inflation. In comparison, operating expenses for fiscal year 2020 benefited by $1.4 million from a Paycheck Protection Program (PPP) loan secured to retain employees supporting the essential agricultural industry during the COVID-19 pandemic, which has since been forgiven.

 

 

 

 

  ○ The full year operating expense ratio was 96.3%. This 820 basis point improvement was a function of increased revenues and effective cost management.
  ○ The net loss for 2021 was $16.6 million as compared with a net loss of $20.2 million in 2020, an 17.9% improvement. Adjusted EBITDA for the full year in 2021 improved by 21.2% to a loss of $8.7 million as compared with a loss of $11.0 million in 2020. Both metrics benefited from the increases in net sales and gross profit. Adjusted EBITDA is further described under “Use of Non-GAAP Financial Information” below.
  ○ Cash used in operations for the full year 2021 was $10 million, as compared with a use of cash of $16 million in 2020. Cash used in operations for the full year 2020 benefited from $1.7 million in proceeds from the PPP loan.

 

Conference Call and Webcast

 

Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations’ fourth quarter and full year 2021 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information:

 

Q4 2021 Conference Call and Webcast

 

Date: Monday, March 28, 2022

Time: 4:30 p.m. Eastern

U.S. Dial-in: 1-844-612-2103

International Dial-in: 1-918-922-3145

Conference ID: 2075879

Webcast: https://edge.media-server.com/mmc/p/7u5z3faa

 

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

 

A telephonic playback of the call will be available through April 6, 2022. To listen, call 1-855-859-2056 in the United States, or 1-404-537-3406 internationally. Please use the conference ID number 2075879. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: https://investors.marronebio.com/

 

About Marrone Bio Innovations

 

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to environmentally sustainable farming practices through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of 18 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of more than 500 issued and pending patents. Our end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. Marrone Bio’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, environmentally sound solutions in agriculture.

 

 

 

 

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.

 

Non-GAAP Financial Measures

 

This earnings release discusses Adjusted EBITDA which is not a financial measure as defined by GAAP. This financial measure is presented as a supplemental measure of operating performance because we believe it can aid in, and enhance, the understanding of our financial results. In addition, we use Adjusted EBITDA as a measure internally for budgeting purposes.

 

We define Adjusted EBITDA as net income (loss) before (1) interest expense (income), net, (2) income tax expense (benefit), (3) depreciation, (4) amortization of intangible assets, (5) stock-based compensation expense, plus (6) from time to time, certain other items which are specific transaction-related items. Other companies may define or calculate this measure differently, limiting the usefulness as a comparative measure. Because of this limitation, this non-GAAP financial measure should not be considered in isolation or as substitute for or superior to performance measures calculated in accordance with GAAP and should be read in conjunction with the financial statement tables.

 

GAAP to non-GAAP Reconciliation        
         
   YEAR ENDED   YEAR ENDED 
   DECEMBER 31,   DECEMBER 31, 
   2021   2020 
Net Loss (AS REPORTED)  $(16,554)  $(20,168)
Taxes   45    29 
Interest expense   1,570    1,443 
Depreciation and amortization   3,531    3,558 
EBITDA  $(11,408)  $(15,138)
Stock based compensation   3,351    3,595 
Loss on modification of warrants   —    72 
Loss on issuance of new warrants   —    1,391 
Change in fair value of contingent consideration   (639)   445 
Reduction in expenses related to PPP funds   —    (1,396)
Adjusted EBITDA  $(8,696)  $(11,031)

 

Marrone Bio Innovations Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing the company’s views as of any subsequent date. Examples of such statements include financial guidance and other statements regarding the company’s future revenue growth, margins, operating expenses, and other financial results; the potential benefits and value of the company’s products and statements regarding the potential completion of a merger transaction with Bioceres Crop Solutions. Such forward-looking statements are based on information available to the company as of the date of this release and involve a number of risks and uncertainties, some beyond the company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the company’s products, any difficulty in expanding the company’s sales and marketing infrastructure or marketing the company’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, adverse actions by distributors, manufacturers, regulatory agencies, shareholders and other relevant third parties and costs associated with the Bioceres transaction or any other strategic acquisitions or other business opportunities we elect to pursue, failure to satisfy any of the other conditions to the proposed transaction with Bioceres on a timely basis or at all, and the occurrence of events that may give rise to a right of one or both of the parties to terminate the definitive agreement with Bioceres. Additional information that could lead to material changes in the company’s performance is contained in its filings with the Securities and Exchange Commission. The company is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

 

Marrone Bio Innovations Contact:

Telephone: 530-750-2800

info@marronebio.com

 

 

 

 

MARRONE BIO INNOVATIONS, INC.
Consolidated Balance Sheets
(Unaudited, In Thousands, Except Par Value)

 

   DECEMBER 31,   DECEMBER 31, 
   2021   2020 
         
Assets          
Current assets:          
Cash and cash equivalents  $19,623   $15,841 
Accounts receivable   13,211    10,113 
Inventories   8,633    6,618 
Prepaid expenses and other current assets   1,211    1,688 
Total current assets   42,678    34,260 
Property, plant and equipment, net   12,676    12,565 
Right of use assets, net   3,637    3,760 
Intangible assets, net   19,011    21,383 
Goodwill   6,740    6,740 
Restricted cash   1,560    1,560 
Other assets   754    929 
Total assets  $87,056   $81,197 
           
Liabilities and stockholders' equity          
Current liabilities:          
Accounts payable  $2,687   $1,895 
Accrued liabilities   14,851    11,650 
Deferred revenue, current portion   360    374 
Lease liability, current portion   1,381    1,008 
Debt, current portion, net   25,909    9,301 
Total current liabilities   45,188    24,228 
Deferred revenue, less current portion   1,165    1,628 
Lease liability, less current portion   2,511    3,050 
Debt, less current portion, net   7,691    11,479 
Debt due to related parties   —    7,300 
Other liabilities   848    2,102 
Total liabilities   57,403    49,787 
Commitments and contingencies          
Stockholders' equity:          
Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at December 31, 2021 and 2020   —    — 
Common stock: $0.00001 par value; 250,000 shares authorized, 182,224 and 167,478 shares issued and outstanding as of December 31, 2021 and 2020, respectively   1    1 
Additional paid in capital   387,023    372,226 
Accumulated deficit   (357,371)   (340,817)
Total stockholders' equity   29,653    31,410 
Total liabilities and stockholders' equity  $87,056   $81,197 

 

 

 

 

MARRONE BIO INNOVATIONS, INC.
Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
(Unaudited)

 

   DECEMBER 31,   DECEMBER 31, 
   2021   2020 
Revenues:          
Product  $43,812   $37,915 
License   498    459 
Total revenues   44,310    38,374 
Cost of product revenues   17,064    15,505 
Gross profit   27,246    22,869 
Operating Expenses:          
Research, development and patent   12,077    11,330 
Selling, general and administrative   30,573    28,734 
Total operating expenses   42,650    40,064 
Loss from operations   (15,404)   (17,195)
Other income (expense):          
Interest expense   (1,570)   (1,443)
Loss on modification of warrants   —    (72)
Loss on issuance of new warrants   —    (1,391)
Change in fair value of contingent consideration   639    (445)
Other income, net   (174)   407 
Total other expense, net   (1,105)   (2,944)
Net loss before income taxes   (16,509)   (20,139)
Income tax expense   (45)   (29)
Net Loss  $(16,554)  $(20,168)
Basic and diluted net loss per common share:  $(0.09)  $(0.14)
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:   174,832    148,892 

 

 

 

 

MARRONE BIO INNOVATIONS, INC.
Consolidated Statements of Cash Flows
(Unaudited – In Thousands)

 

   DECEMBER 31,   DECEMBER 31, 
   2021   2020 
Cash flows from operating activities          
Net loss  $(16,554)  $(20,168)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   3,531    3,558 
Gain on disposal of equipment   —    (9)
Change in inventory reserves   (35)   (139)
Right of use assets amortization   1,036    807 
Share-based compensation   3,351    3,595 
Non-cash interest expense   179    226 
Loss on modification of warrants   —    72 
Loss on issuance of new warrants   —    1,391 
Change in fair value of contingent consideration   (639)   445 
Net changes in operating assets and liabilities:          
Accounts receivable   (3,098)   (4,188)
Inventories   (1,980)   1,670 
Prepaid Expenses and other assets   652    (219)
Accounts payable   585    (1,409)
Accrued and other liabilities   4,718    (148)
Lease Liability   (1,079)   (825)
Deferred revenue   (628)   (618)
Net cash used in operating activities   (9,961)   (15,959)
Cash flows from investing activities          
Payment of consideration in connection with previous asset purchase   (750)   (1,240)
Purchases of property, plant and equipment   (1,093)   (559)
Proceeds from sale of equipment   —    2 
Net cash used in investing activities   (1,843)   (1,797)
Cash flows from financing activities          
Proceeds from issuance of debt   —    202 
Proceeds from secured borrowings   43,340    40,127 
Repayment in secured borrowings   (37,476)   (34,790)
Repayment of debt   (372)   (524)
Exercise of stock options   —    108 
Equity offering costs   —    (104)
Net settlement of options   87    — 
Proceeds from employee stock purchase plan   287    254 
Exercise of warrants   9,720    22,072 
Net cash provided by financing activities   15,586    27,345 
Net increase in cash and cash equivalents and restricted cash   3,782    9,589 
Cash and cash equivalents and restricted cash, beginning of period   17,401    7,812 
Cash and cash equivalents and restricted cash, end of period  $21,183   $17,401 
           
Supplemental disclosure of cash flow information          
Cash paid for interest  $1,383   $1,166 
Supplemental disclosure of non-cash investing and financing activities          
Property, plant and equipment included in accounts payable and accrued liabilities  $207   $44 
Right of use assets (non-cash) acquired  $913   $— 
Conversion of accrued liabilities into equity associated with the granting of restricted stock units  $348   $632 
Contingent consideration milestone settled in common shares  $1,004   $— 

 

 

 

 EX-101.SCH 3 mbii-20220328.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mbii-20220328_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mbii-20220328_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Mar. 28, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 28, 2022
Entity File Number 001-36030
Entity Registrant Name MARRONE BIO INNOVATIONS, INC.
Entity Central Index Key 0001441693
Entity Tax Identification Number 20-5137161
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7780-420 Brier Creek Parkway
Entity Address, City or Town Raleigh
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27617
City Area Code (530)
Local Phone Number 750-2800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.00001 par value
Trading Symbol MBII
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001441693 2022-03-28 2022-03-28 iso4217:USD shares iso4217:USD shares 0001441693 false 8-K 2022-03-28 MARRONE BIO INNOVATIONS, INC. DE 001-36030 20-5137161 7780-420 Brier Creek Parkway Raleigh NC 27617 (530) 750-2800 false false false false Common Stock, $0.00001 par value MBII NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://marronebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm mbii-20220328.xsd mbii-20220328_lab.xml mbii-20220328_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "mbii-20220328_lab.xml" ] }, "presentationLink": { "local": [ "mbii-20220328_pre.xml" ] }, "schema": { "local": [ "mbii-20220328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MBII", "nsuri": "http://marronebio.com/20220328", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-28to2022-03-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://marronebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-28to2022-03-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://marronebio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-007885-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-007885-xbrl.zip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end